Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 6/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.37 |
| ▸ | SCN4A | P35499 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | G6PD | P11413 | 1/20 | 0.32 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5544029 | 0.86 | — | — | |
| SCHEMBL693311 | 0.86 | KIF11 (0.41) | KIF11MAPTEPHX2SCN4AMEN1 | |
| SCHEMBL693968 | 0.80 | KIF11 (0.38) | KIF11MAPTEPHX2SCN4APTPN5 | |
| SCHEMBL146618 | 0.79 | KIF11 (0.37) | KIF11EPHX2SCN4APTPN5HSD17B10 | |
| SCHEMBL697831 | 0.78 | KIF11 (0.37) | KIF11MAPTEPHX2SCN4APTPN5 | |
| SCHEMBL27988163 | 0.78 | PDE2A (0.38) | KIF11MAPTEPHX2SCN4AMEN1 | |
| SCHEMBL5541424 | 0.75 | BCL2L1 (0.36) | KIF11MAPTHSD17B10 | |
| SCHEMBL5544691 | 0.75 | NPC1 (0.41) | KIF11SCN4ADYRK1AHSD17B10 | |
| SCHEMBL693728 | 0.74 | DYRK1A (0.37) | KIF11MAPTEPHX2SCN4AMEN1 | |
| SCHEMBL27988143 | 0.74 | HTR2A (0.36) | KIF11MAPTEPHX2SCN4ADYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10076517-B2 | Methods and pharmaceutical compositions for the treatment of fibrosis | INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE KA RECHERCHE MÉDICALE (FR) | 2018-09-18 | — | — | US | claimed |
| EP-2611774-B1 | DI-AZETIDINYL DIAMIDE AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-03-18 | — | — | EP | claimed |
| US-8962607-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-02-24 | — | — | US | claimed |
| EP-2421823-B1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-14 | — | — | EP | claimed |
| US-20140243305-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (US) | 2014-08-28 | — | — | US | claimed |
| US-8759533-B2 | Di-azetidinyl diamide as monoacylglcerol lipase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2014-06-24 | — | — | US | claimed |
| US-20130244998-A1 | PIPERIDIN-4-YL-AZETIDINE DIAMIDES AS MONOACYLGLCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA, NV (BE) | 2013-09-19 | — | — | US | claimed |
| EP-2629851-A1 | PIPERIDIN-4-YL-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | Janssen Pharmaceutica N.V. (BE) | 2013-08-28 | — | — | EP | claimed |
| US-8513423-B2 | Piperidin-4-yl-azetidine diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2013-08-20 | — | — | US | claimed |
| US-20130196968-A1 | DI-AZETIDINYL DIAMIDE AS MONOACYLGLCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA, NV (BE) | 2013-08-01 | — | — | US | claimed |
| US-8399454-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2013-03-19 | — | — | US | claimed |
| WO-2012054716-A1 | PIPERIDIN-4-YL-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV. (BE) | 2012-04-26 | — | — | WO | claimed |
| WO-2012030907-A1 | DI-AZETIDINYL DIAMIDE AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-03-08 | — | — | WO | claimed |
| US-20120058986-A1 | DI-AZETIDINYL DIAMIDE AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-03-08 | — | — | US | claimed |
| EP-2421823-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | Janssen Pharmaceutica N.V. (BE) | 2012-02-29 | — | — | EP | claimed |
| EP-2421824-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | Janssen Pharmaceutica N.V. (BE) | 2012-02-29 | — | — | EP | claimed |
| US-20110015170-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-01-20 | — | — | US | claimed |
| US-20100324012-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-23 | — | — | US | claimed |
| WO-2010124114-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | claimed |
| WO-2010124086-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10076517-B2 | Methods and pharmaceutical compositions for the treatment of fibrosis | LIPA, MGLL, PNLIP | KIF11 3934/4885MAPT 4747/4885EPHX2 451/4885 |
| US-20110015170-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | KIF11 4060/4885MAPT 4519/4885EPHX2 647/4885 |
| US-20130196968-A1 | DI-AZETIDINYL DIAMIDE AS MONOACYLGLCEROL LIPASE INHIBITORS | MGLL, PNLIP, LPL | KIF11 2971/4885MAPT 3802/4885EPHX2 519/4885 |
| US-20140243305-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | KIF11 4060/4885MAPT 4519/4885EPHX2 647/4885 |
| US-20120058986-A1 | DI-AZETIDINYL DIAMIDE AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | KIF11 3713/4885MAPT 4239/4885EPHX2 589/4885 |
| US-20100324012-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | KIF11 4060/4885MAPT 4519/4885EPHX2 647/4885 |
| US-20130244998-A1 | PIPERIDIN-4-YL-AZETIDINE DIAMIDES AS MONOACYLGLCEROL LIPASE INHIBITORS | MGLL, PNLIP, LPL | KIF11 3203/4885MAPT 4290/4885EPHX2 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.